OPRX
$5.99-0.16 (-2.60%)
OptimizeRx Corporation operates as a digital healthcare technology company.
Recent News
How The OptimizeRx (OPRX) Narrative Is Shifting As Guidance Resets And Valuation Expectations Reprice
The updated analyst work on OptimizeRx centers on a sharp reset in the stock’s fair value estimate, with the price target revised from US$24.33 to US$14.50, a cut of roughly 40%. That shift lines up with Street commentary that balances solid Q4 revenue and EBITDA with lower 2026 revenue expectations and mixed views on pharma marketing budgets and policy headwinds. Read on to see how to track this evolving narrative and what to watch as new data points come through. Analyst Price Targets don't...
Is OptimizeRx (OPRX) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for March 16th
OPRX, NVST and STRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 16, 2026.
OptimizeRx Corporation Q4 2025 Earnings Call Summary
Moby summary of OptimizeRx Corporation's Q4 2025 earnings call
OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
OptimizeRx Corp (OPRX) reports robust Q4 performance with $32.2 million in revenue, while navigating market shifts and setting conservative 2026 guidance.